雾化吸入不同剂量重组人干扰素α1b治疗小儿急性毛细支气管炎的疗效比较

摘要

目的 对比雾化吸入不同剂量重组人干扰素α1b治疗小儿急性毛细支气管炎的疗效.方法 选择我院儿科2014年10月至2016年8月收治的120例毛细支气管炎患儿为研究对象,根据随机数表法将患儿分为A、B、C三组,每组40例.A组予常规治疗,B组和C组分别在常规治疗基础上联合雾化吸入重组人干扰素α1b,剂量分别为2μg/kg、4μg/kg,疗程7 d.疗程结束后,比较两组患儿喘息缓解时间、哮鸣音消失时间、咳嗽消失时间及住院时间以及治疗有效率.结果 治疗后,B组、C组患儿喘息缓解时间、哮鸣音消失时间、咳嗽消失时间及住院时间分别为(3.24±1.32)d、(5.42±1.34)d、(6.36±1.40)d、(5.62±1.29)d和(5.37±1.28)d、(5.37±1.28)d、(6.21±1.32)d、(5.41±1.23)d,均明显短于A组的(4.51±1.47)d、(6.79±1.62)d、(7.91±1.57)d、(7.92±1.91)d,差异均有统计学意义(P<0.05);B组、C组患儿的治疗有效率分别为92.50%、95.00%,明显高于A组的75.00%,差异均有统计学意义(P<0.05);而B组和C组患儿的上述各项指标比较差异均无统计学意义(P>0.05).三组患儿均未见未见发热、皮疹等药物相关不良反应,治疗期间血常规及肝肾功能检查均正常.结论 常规治疗基础上联合雾化吸入低剂量(2μg/kg)的重组人干扰素α1b治疗小儿急性毛细支气管炎具有确切的临床疗效,安全性较高.%Objective To explore the effects of different doses of recombinant human interferonα1b in chil-dren with acute bronchiolitis. Methods A total of 120 children with bronchiolitis, who admitted to Department of Pedi-atrics of our hospital from October 2014 to August 2016, were selected and divided into the A, B and C group according to random number table method, with 40 cases in each group. The A group received conventional treatment, and the B group and C group were treated with conventional treatment combined with inhalation of recombinant human interferonα1b at dose of 2μg/kg, 4μg/kg, for 7 d. After the course of treatment, the asthmatic remission time, wheezing disappear-ance time, cough disappeared time and hospitalization time and the effective rate of treatment of the two groups were compared. Results After the treatment, the asthmatic remission time, wheezing disappearance time, cough disappeared time and hospitalization time of the B group and C group were respectively (3.24±1.32) d, (5.42±1.34) d, (6.36±1.40) d, (5.62 ± 1.29) d and (5.37 ± 1.28) d, (5.37 ± 1.28) d, (6.21 ± 1.32) d, (5.41 ± 1.23) d, which were significantly shorter than (4.51±1.47) d, (6.79±1.62) d, (7.91±1.57) d, (7.92±1.91) d of the A group (P<0.05). The effective rate of the B group and C group were 92.50%and 95.00%, respectively, which were significantly higher than 75.00%of the A group (P<0.05). There were of no statistical difference between the B group and the C group in the above indexes (P>0.05). There were no drug-related adverse reactions such as fever and rash, and blood and liver and kidney function tests were normal dur-ing the treatment. Conclusion The inhalation of low dose (2μg/kg) recombinant human interferonα1b combined with conventional treatment has exact clinical efficacy for acute bronchiolitis in children, with rare adverse reaction.